The National Foundation for Cancer Research (NFCR) is happy to announce that we are a finalist in the 2022 Moxie Awards. The Moxie Award honors the achievements of growing businesses, nonprofits, and associations in the DC metro community.
This year marks the first time NFCR has been a finalist for this honor.
Per their website, “organizations are recognized for having demonstrated boldness and innovation as an integral part of their growth strategy.”
Earlier this year, NFCR welcomed three new Board Directors to help us amplify our impact on cancer patients.
Additionally, NFCR distinguishes itself from other cancer charities by funding research others won’t, such as early stage metastasis research. Consequently, this research often leads to the development of critical new fields of cancer research.
Other bold initiatives NFCR is proud to push forward include:
GBM AGILE which will serve as a more efficient, cost-effective, and accelerated drug development model, helping cancer patients survive even the deadliest cancers
The Women’s Venture Competition, in partnership with the AIM-HI Accelerator Fund empowering women scientists-entrepreneurs in oncology
“I want to congratulate our team for dreaming big and working hard to innovate for the benefit of cancer patients. Our organization is proud to be in the DC Metro Community and serve a wider population,” shares Brian Wachtel, NFCR Executive Director.
The 2022 Moxie Award Chair, Katie Jordan, announced the finalists, sharing:
“This year’s finalists truly represent the spirit of Moxie and we are excited to help tell the stories of how they have persevered through a difficult time and continue to innovate. We look forward to revealing the winners at the 2022 Moxie Award celebration on October 26, 2022, at The Ritz-Carlton in Tysons Corner.”
Learn more about this award and see other finalists at https://moxieaward.com.
Stay connected with the cancer community! Receive NFCR’s monthly e-newsletter featuring patient stories, cancer prevention tips, etc. Sign up here.